Figure 6
Figure 6. GATA2 binding is enriched in the +37-kb chromatin region of the Cebpa gene. (A) The configuration of the murine Cebpa gene. The consensus DNA-binding sequences for transcription factors are shown as indicated. The positions of the PCR amplicons used in the qChIP assays are indicated by 3-headed arrows. (B) The DNA-binding activity of GATA2 to the Cebpa promoter and +37-kb region in ΔCF/ΔCF BMMCs was examined using qChIP assays. Black and gray bars indicate 4-OHT-treated (for 3 days) and untreated ΔCF/ΔCF BMMCs, respectively. N = 4. The control experiments were performed using rabbit IgG in place of anti-GATA2 antibodies. (C) qChIP assays of the Cebpa promoter and +37-kb regions were performed with anti RUNX1 (left 2 panels) and PU.1 (right 2 panels) antibodies. (D) qChIP assays of the Cebpa promoter and +2- and +37-kb regions were performed with antiacetylated histone H3 antibodies. In C and D, the samples were prepared from ΔCF/ΔCF BMMCs treated with 4-OHT for 0, 3, and 6 days (D0, D3, and D6). Gray bars indicate the control experiments using rabbit IgG in place of the indicated antibodies. *P < .05; **P < .01 (compared with the data for D0). N = 4.

GATA2 binding is enriched in the +37-kb chromatin region of the Cebpa gene. (A) The configuration of the murine Cebpa gene. The consensus DNA-binding sequences for transcription factors are shown as indicated. The positions of the PCR amplicons used in the qChIP assays are indicated by 3-headed arrows. (B) The DNA-binding activity of GATA2 to the Cebpa promoter and +37-kb region in ΔCF/ΔCF BMMCs was examined using qChIP assays. Black and gray bars indicate 4-OHT-treated (for 3 days) and untreated ΔCF/ΔCF BMMCs, respectively. N = 4. The control experiments were performed using rabbit IgG in place of anti-GATA2 antibodies. (C) qChIP assays of the Cebpa promoter and +37-kb regions were performed with anti RUNX1 (left 2 panels) and PU.1 (right 2 panels) antibodies. (D) qChIP assays of the Cebpa promoter and +2- and +37-kb regions were performed with antiacetylated histone H3 antibodies. In C and D, the samples were prepared from ΔCF/ΔCF BMMCs treated with 4-OHT for 0, 3, and 6 days (D0, D3, and D6). Gray bars indicate the control experiments using rabbit IgG in place of the indicated antibodies. *P < .05; **P < .01 (compared with the data for D0). N = 4.

Close Modal

or Create an Account

Close Modal
Close Modal